INOVIO PHARMACEUTICALS, INC. — Form 8-K
Filed July 29, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 25/100
What the filing says
Inovio Pharmaceuticals filed an 8-K on July 29, 2026 disclosing results of operations and financial condition under Item 2.02. No specific financial metrics, dollar amounts, dates of material transactions, counterparties, or substantive operational changes are provided in the filing header or document metadata supplied. The actual results and details are contained in the full 8-K document text, which was not included in this extract.
Why this rating
Routine quarterly/periodic earnings disclosure. No material transaction, deal, or strategic change disclosed in available text; insufficient data to assess magnitude.
Extracted items
See more from July 29, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.